Instem is a leading supplier of IT solutions and technology-enabled outsourced services to the global life sciences market. The Group is focussed on the early development stages, from late discovery and lead optimisation through to Phase IIa clinical evaluation and regulatory submission management. Instem’s solutions increase productivity and automate the processes that lead to safer and more effective drug and chemical products. As the number one global provider, management estimates that approximately half of the world’s preclinical drug safety data has been collected over the last 20 years using Instem software.
Instem has over 500 customers with its blue chip customer base consisting of the leading pharmaceutical, medical device, chemical and contract research organisations as well as academic, government and privately funded research institutions across many sites worldwide. These include all of the top 25 pharmaceutical and biotech companies such as GlaxoSmithKline and AstraZeneca.
The business has been accelerating its growth trajectory, both organically and acquisitively, by introducing new software solutions for the Early Development market, providing technology-enabled outsourced services and extending its presence in the Asia-Pacific, a region where the market has been growing strongly and Instem’s penetration had been modest.
Instem clients are reducing their research and development timelines generating significant patent-protected revenue
|2016||Acquisition of NOTOCORD® in September|
|2016||Acquisition of Samarind Limited in May|
|2016||Placing of 2,500,000 New Ordinary Shares to raise £5.0 million|
|2013||Acquisition of Perceptive Instruments in November|
|2013||Acquisition of Logos Technologies in May|
|2011||Acquisition of BioWisdom Ltd in March|
|2010||Placing raising £9.15 million and Admission to the AIM market of the London Stock Exchange|
|2010||Repayment of outstanding Alchemy debt
Chinese subsidiary established in Shanghai
|2002||Secondary MBO for an EV of £11.8m
Focus on dominating niche in Early Development Safety Assessment & repaying debt
|2001||Provantis software suite launched|
|1999||Instem Life Science Systems acquired Fraser-Williams Data Systems|
|1998||Instem Life Science Systems demerged from Instem plc|
|1997||Instem plc taken private by management backed by Alchemy Partners|
|1996||Acquired Apoloco - a pharma software business|
|1994||Phil Reason appointed to run Instem Life Science Systems|
|1992||Instem Life Science Systems division formally established as part of Instem plc|